Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

PURPOSE: Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We present an updated RFS analysis on the ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauschild, Axel, Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, Gasal, Eduard, Kefford, Richard, Kirkwood, John M., Long, Georgina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159/
https://www.ncbi.nlm.nih.gov/pubmed/30343620
http://dx.doi.org/10.1200/JCO.18.01219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159/
https://www.ncbi.nlm.nih.gov/pubmed/30343620
http://dx.doi.org/10.1200/JCO.18.01219

Ejemplares similares